New Observations Made in Asthma-COPD Overlap Syndrome (ACOS) Patients – Lung Disease News


Lung Disease News

New Observations Made in Asthma-COPD Overlap Syndrome (ACOS) Patients
Lung Disease News
Asthma-COPD overlap syndrome (ACOS) accounts for 15 to 25% of obstructive airway diseases and patients affected with ACOS usually exhibit worse symptoms and clinical outcomes when compared to patients with asthma or chronic obstructive pulmonary …

View full post on asthma – Google News

On-Chip Processor An Advance in Point-of-Care Asthma and Tuberculosis Diagnostics – Lung Disease News


Lung Disease News

On-Chip Processor An Advance in Point-of-Care Asthma and Tuberculosis Diagnostics
Lung Disease News
Asthma pathogenesis of involves airway inflammation, airway remodeling, and hyperreactivity, which lead to difficulty in breathing that can be deadly if not properly controlled. Steroid medications can successfully treat asthma in most cases, but side
Lab on a Chip Acoustofluidic Sputum Liquefaction Device for Safe Asthma and AZoNano.com
New Lab-on-a-Chip to identify Asthma as well as TuberculosisThe Wiire (blog)
On-Chip Processor the First Step in Point-of-Care Tuberculosis and Asthma Infection Control Today
NDTV –Economic Times
all 20 news articles »

View full post on asthma – Google News

Invion and Hovione Partner to Develop Inhaled Zafirlukast for Asthma – Lung Disease News


Lung Disease News

Invion and Hovione Partner to Develop Inhaled Zafirlukast for Asthma
Lung Disease News
Australia-based pharmaceutical company Invion Ltd. recently signed a partnership agreement with Hovione Scientia Ltd., a multinational pharmaceutical company focused on developing inhaled therapeutics, for the advancement of INV104 (zafirlukast) as a …

and more »

View full post on asthma – Google News

Invion and Hovione Partner to Develop Inhaled Zafirlukast for Asthma Lung … – Lung Disease News

Invion and Hovione Partner to Develop Inhaled Zafirlukast for Asthma Lung
Lung Disease News
GSK Expands Its COPD And Asthma Portfolio Across The US. Australia-based pharmaceutical company Invion Ltd. recently signed a partnership agreement with Hovione Scientia Ltd., a multinational pharmaceutical company focused on developing inhaled …

View full post on asthma – Google News

Airway Resistance Measurements Shown to Help Effectively Differentiate … – Lung Disease News


Lung Disease News

Airway Resistance Measurements Shown to Help Effectively Differentiate
Lung Disease News
To examine the contribution of RAW and sGAW to a diagnosis of obstructive airways disease and their role in differentiating asthma from COPD, in the study titled “Airways resistance and specific conductance for the diagnosis of obstructive airways

View full post on asthma – Google News

Ambient air pollution, lung function, and airway responsiveness in asthmatic children.

Related Articles

Ambient air pollution, lung function, and airway responsiveness in asthmatic children.

J Allergy Clin Immunol. 2015 Jun 29;

Authors: Ierodiakonou D, Zanobetti A, Coull BA, Melly S, Postma DS, Boezen HM, Vonk JM, Williams PV, Shapiro GG, McKone EF, Hallstrand TS, Koenig JQ, Schildcrout JS, Lumley T, Fuhlbrigge AN, Koutrakis P, Schwartz J, Weiss ST, Gold DR, Childhood Asthma Management Program Research Group

Abstract
BACKGROUND: Although ambient air pollution has been linked to reduced lung function in healthy children, longitudinal analyses of pollution effects in asthmatic patients are lacking.
OBJECTIVE: We sought to investigate pollution effects in a longitudinal asthma study and effect modification by controller medications.
METHODS: We examined associations of lung function and methacholine responsiveness (PC20) with ozone, carbon monoxide (CO), nitrogen dioxide, and sulfur dioxide concentrations in 1003 asthmatic children participating in a 4-year clinical trial. We further investigated whether budesonide and nedocromil modified pollution effects. Daily pollutant concentrations were linked to ZIP/postal code of residence. Linear mixed models tested associations of within-subject pollutant concentrations with FEV1 and forced vital capacity (FVC) percent predicted, FEV1/FVC ratio, and PC20, adjusting for seasonality and confounders.
RESULTS: Same-day and 1-week average CO concentrations were negatively associated with postbronchodilator percent predicted FEV1 (change per interquartile range, -0.33 [95% CI, -0.49 to -0.16] and -0.41 [95% CI, -0.62 to -0.21], respectively) and FVC (-0.19 [95% CI, -0.25 to -0.07] and -0.25 [95% CI, -0.43 to -0.07], respectively). Longer-term 4-month CO averages were negatively associated with prebronchodilator percent predicted FEV1 and FVC (-0.36 [95% CI, -0.62 to -0.10] and -0.21 [95% CI, -0.42 to -0.01], respectively). Four-month averaged CO and ozone concentrations were negatively associated with FEV1/FVC ratio (P < .05). Increased 4-month average nitrogen dioxide concentrations were associated with reduced postbronchodilator FEV1 and FVC percent predicted. Long-term exposures to sulfur dioxide were associated with reduced PC20 (percent change per interquartile range, -6% [95% CI, -11% to -1.5%]). Treatment augmented the negative short-term CO effect on PC20.
CONCLUSIONS: Air pollution adversely influences lung function and PC20 in asthmatic children. Treatment with controller medications might not protect but rather worsens the effects of CO on PC20. This clinical trial design evaluates modification of pollution effects by treatment without confounding by indication.

PMID: 26187234 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

AstraZeneca Signs Partnership With Kyowa Hakko Kirin To Commercialize Asthma … – Lung Disease News


Lung Disease News

AstraZeneca Signs Partnership With Kyowa Hakko Kirin To Commercialize Asthma
Lung Disease News
It will also retain responsibility for furthering the drug's research and development in Japan, and keep hold of rights to participate in some of AstraZeneca's commercial activities. AstraZeneca will be accountable for all sales and marketing in asthma

View full post on asthma – Google News

AstraZeneca Signs Partnership With Kyowa Hakko Kirin To Commercialize … – Lung Disease News


Lung Disease News

AstraZeneca Signs Partnership With Kyowa Hakko Kirin To Commercialize
Lung Disease News
It will also retain responsibility for furthering the drug's research and development in Japan, and keep hold of rights to participate in some of AstraZeneca's commercial activities. AstraZeneca will be accountable for all sales and marketing in asthma

View full post on asthma – Google News

Chicago-based Clinical Trial Exploring Coordinated Healthcare Interventions … – Lung Disease News


Lung Disease News

Chicago-based Clinical Trial Exploring Coordinated Healthcare Interventions
Lung Disease News
In Chicago, the rates of asthma in children are remarkably high, and the condition has been found to have a high incidence among African-American children. The CHICAGO trial (Coordinated Healthcare Interventions for Childhood Asthma Gaps in …

View full post on asthma – Google News